Interplay between bladder microbiota and overactive bladder symptom severity: a cross‐sectional study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Interplay between bladder microbiota and overactive bladder symptom severity: a cross‐sectional study ; volume:22 ; number:1 ; day:19 ; month:3 ; year:2022 ; pages:1-10 ; date:12.2022
BMC urology ; 22, Heft 1 (19.3.2022), 1-10, 12.2022
- Urheber
-
Li, Kun
Chen, Chunxiao
Zeng, Jiarong
Wen, Yuehui
Chen, Weihong
Zhao, Jie
Wu, Peng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-022-00990-0
- URN
-
urn:nbn:de:101:1-2022061109143114980232
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:19 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Kun
- Chen, Chunxiao
- Zeng, Jiarong
- Wen, Yuehui
- Chen, Weihong
- Zhao, Jie
- Wu, Peng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer
Association between meniscal extrusion and disease severity in knee osteoarthritis: a retrospective case-control study
Footprint of export-related GHG emissions from Latin America and the Caribbean
An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer
Overactive bladder : Fragen und Antworten
Overactive Bladder - Fragen und Antworten
Overactive bladder induces transient hypertension
Sexualstörungen bei Overactive Bladder und Belastungsinkontinenz
Refractory overactive bladder: a common problem?
Vaginal laser for overactive bladder syndrome
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
circRNA-0015004 act as a ceRNA to promote RCC2 expression in hepatocellular carcinoma
Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer
Association between meniscal extrusion and disease severity in knee osteoarthritis: a retrospective case-control study
Footprint of export-related GHG emissions from Latin America and the Caribbean
An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer
Overactive bladder : Fragen und Antworten
Overactive Bladder - Fragen und Antworten
Overactive bladder induces transient hypertension
Sexualstörungen bei Overactive Bladder und Belastungsinkontinenz
Refractory overactive bladder: a common problem?
Vaginal laser for overactive bladder syndrome
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
circRNA-0015004 act as a ceRNA to promote RCC2 expression in hepatocellular carcinoma
Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer
Association between meniscal extrusion and disease severity in knee osteoarthritis: a retrospective case-control study
Footprint of export-related GHG emissions from Latin America and the Caribbean
An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer
Overactive bladder : Fragen und Antworten
Overactive Bladder - Fragen und Antworten
Overactive bladder induces transient hypertension
Sexualstörungen bei Overactive Bladder und Belastungsinkontinenz
Refractory overactive bladder: a common problem?
Vaginal laser for overactive bladder syndrome
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study